Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03537586
Other study ID # 18-00116
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 29, 2018
Est. completion date June 30, 2026

Study information

Verified date January 2024
Source NYU Langone Health
Contact Nathaniel Smilowitz
Phone 212-263-5656
Email Nathaniel.Smilowitz@nyulangone.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Among patients with stable ischemic heart disease who are referred for coronary angiography, a substantial proportion have non-obstructive coronary artery disease (CAD). Ischemia based on symptoms or stress testing may be due to coronary microvascular dysfunction in up to 40% of these patients. However, the mechanisms and optimal treatment of coronary microvascular dysfunction are unknown. Aberrant platelet activity and inflammation have been hypothesized as mechanisms of microvascular dysfunction. Investigators plan to evaluate association between platelet activity, inflammation, and coronary microvascular dysfunction in stable women referred for coronary angiography, and to identify non-invasive correlates of coronary microvascular dysfunction in these patients.


Description:

The objectives of this study are to 1. Investigate platelet activity and inflammation in patients with and without coronary microvascular disease who are referred for coronary angiography for the evaluation of stable ischemic heart disease and are found to have non-obstructuve epicardial CAD 2. To identify correlates of coronary microvascular dysfunction in non coronary microvascular beds that can be characterized in vivo.


Recruitment information / eligibility

Status Recruiting
Enrollment 165
Est. completion date June 30, 2026
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 125 Years
Eligibility Inclusion Criteria: - Adult women age =18 years referred for coronary angiography - Stable ischemic heart disease, defined by ischemic symptoms and/or myocardial ischemia by stress testing - Administration of aspirin therapy prior to cardiac catheterization Exclusion Criteria: Pre-Cath Exclusion criteria: - Active bleeding and/or bleeding diathesis - Anemia (hemoglobin <9 mg/dl) - Known thrombocytosis (platelet count >500,000) - Know thrombocytopenia (platelet count <100,000) - NSAIDs (e.g., ibuprofen, naproxen) within 3 days - Platelet antagonists other than aspirin and thienopyridines, within 7 days - Prior percutaneous coronary intervention or coronary artery bypass grafting - Acute myocardial infarction within 3 months - Severe valvular heart disease - Cardiogenic shock or mechanical circulatory support - New York Heart Association (NYHA) Functional Class III or IV heart failure - Ejection Fraction <40% - Hypertrophic obstructive cardiomyopathy or severe left ventricular hypertrophy - Pregnancy - Contraindication to intravenous infusion of adenosine during coronary angiography, due to known hypersensitivity to adenosine, known or suspected bronchoconstrictive or bronchospastic lung disease (severe asthma), second- or third-degree AV block (except in patients with a functioning artificial pacemaker), or sinus node disease, such as sick sinus syndrome or symptomatic bradycardia, Angiographic Exclusion criteria: - Obstructive CAD (=50% luminal obstruction in =1 major epicardial coronary arteries by invasive coronary angiography) - Unfavorable coronary artery anatomy for guidewire positioning (as determined by the angiographer or PI)

Study Design


Intervention

Drug:
Bivalirudin
After diagnostic catheterization, intravenous bivalirudin (Angiomax) will be administered as part of the research procedure, and a 6F-guiding catheter without side holes will be used to engage the ostium of the coronary artery.
Adenosine
An intravenous infusion of adenosine (140 µg/kg/min) will be administered via a large peripheral or central vein to induce steady-state maximal hyperemia.
Heparin
Heparin may be used as an alternative to bivalirudin at the discretion of the interventional cardiologist.
Device:
Pressure-Temperature Sensor Guidewire
Abbott's Pressure Wire X will be used to measure fractional flow reserve (FFR), cardiac magnetic resonance (CMR) and Index of Microcirculatory Resistance (IMR) in the Left Anterior Descending (LAD) Artery and major epicardial coronary vessels associated with myocardial ischemia.
Guiding Catheter
Medtronic's 6F Launcher Guide Catheter will be used to engage the left main coronary artery.

Locations

Country Name City State
United States New York University School of Medicine New York New York

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Platelet Activity measured by the Index of Microcirculatory Resistance (IMR) 12 Months
Primary Measure of Inflammation measured by the Index of Microcirculatory Resistance (IMR) 12 Months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Completed NCT04153006 - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed NCT01205776 - EXCEL Clinical Trial N/A
Active, not recruiting NCT04555174 - BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
Recruiting NCT04582877 - Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial N/A
Recruiting NCT04390672 - Multivessel TALENT N/A
Recruiting NCT03265535 - Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
Not yet recruiting NCT04522583 - Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia
Completed NCT02510547 - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Phase 4
Terminated NCT02407626 - Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery N/A
Completed NCT02554006 - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings N/A
Active, not recruiting NCT02189499 - Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent Phase 2
Completed NCT02264717 - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease N/A
Completed NCT02197065 - Pilot Study of Atorvastatin for Orthopedic Surgery Patients Phase 2
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Terminated NCT01892917 - BIOFLOW-III Hungary Satellite Registry N/A
Completed NCT01679886 - Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women N/A
Completed NCT01655043 - Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI Phase 2
Completed NCT01434043 - Diagnostic Accuracy of Cardiac CT Perfusion Compared to PET Imaging